Wednesday 2 June 2021
The UAE Ministry of Health and Prevention (MoHAP) has approved the emergency use of a highly effective new treatment for COVID-19, becoming the first country in the world to both license and enable immediate patient use after the US Food and Drug Administration (FDA) gave an emergency use authorization to the antibody treatment.
Sotrovimab (Vir-7831), the new treatment healthcare company GSK, offers the prospect of reducing hospitalization for more than 24 hours and fatalities by as much as 85% when administered to patients as an early treatment for COVID-19.
The UAE has authorized the emergency use of Sotrovimab, a monoclonal antibody, for the treatment of patients aged 12 years or older with mild to moderate COVID-19 disease who are at risk of progression to hospitalization or death. In pre-clinical studies, Sotrovimab has demonstrated effectiveness as a monotherapy against widely circulating variants of the disease.
The treatment is expected to help speed up the recovery of patients, reducing COVID-19-related deaths and hospitalization period in intensive care units.
From the earliest days of the pandemic, MoHAP's strategy has centered on embracing promising new technologies, including tests, vaccines, and treatments in the effort to curtail the spread of COVID-19. The UAE has always been proactive in approving and registering global innovative medicines, according to an innovative mechanism developed to evaluate and approve first-of-its-kind medicines.
The UAE has become the first country in the world to license and bring GSK treatments into use thanks to a long-established strategic partnership with the global healthcare company.